CASTLE BIOSCIENCES INC — Director's Dealing 2021

Mar 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CASTLE BIOSCIENCES INC (CSTL)
CIK: 0001447362
Period of Report: 2021-03-16

Reporting Person: KABAKOFF DAVID S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-16	Common Stock	S	30000	$61.2117	Disposed	853577	Indirect
2021-03-16	Common Stock	S	30000	$63.7569	Disposed	823577	Indirect
2021-03-16	Common Stock	S	40000	$64.6264	Disposed	783577	Indirect
2021-03-16	Common Stock	S	20000	$65.7283	Disposed	763577	Indirect
2021-03-17	Common Stock	S	10000	$66.1365	Disposed	753577	Indirect

Footnotes

F1: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020.

F2: This transaction was executed in multiple trades at prices ranging from $61.1168 to $61.3623, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein.

F4: This transaction was executed in multiple trades at prices ranging from $63.4256 to $63.9355, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This transaction was executed in multiple trades at prices ranging from $64.4900 to $64.7471, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: This transaction was executed in multiple trades at prices ranging from $65.7011 to $65.7554, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.